FONTANA DILETTA

Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante, V. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. Intervento presentato a: Barcelona BioMed Conferences. AI in Drug Discovery and Biomedicine, Barcelona, Spain. Detail

Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante Varillas, S. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. PLOS ONE, 20(1) [10.1371/journal.pone.0308747]. Detail

Crippa, V., Fontana, D., Civettini, I., Mologni, L., Piazza, R., Gambacorti Passerini, C., et al. (2024). Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer. Intervento presentato a: AACR Annual Meeting 2024 - April 5 - 10, 2024, San Diego, Ca, Usa. Detail

Malighetti, F., Villa, M., Sala, E., Geeta, G., Arosio, G., Gemelli, M., et al. (2024). Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy. Intervento presentato a: American Association for Cancer Research Annual Meeting 2024 - April 5-10, 2024, San Diego, CA [10.1158/1538-7445.am2024-987]. Detail

Poggio, P., Rocca, S., Fusella, F., Ferretti, R., Ala, U., D'Anna, F., et al. (2024). miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia. SCIENTIFIC REPORTS, 14(1) [10.1038/s41598-024-65404-7]. Detail